The Medicines Management Programme recommends Brabio as the preferred product for glatiramer acetate on the High Tech Arrangement.

Clinicians should give due consideration to prescribing Brabio when issuing a prescription for glatiramer acetate on the High Tech Arrangement. Implementation of this recommendation would lead to significant savings for the health service, in the order of millions of euros.

Resources to support prescribing of the preferred product Brabio are located in the Related Files section below:

  •  Questions and Answers for Healthcare Professionals.
  •  Patient Information Sheet.
  •  MMP Product Information Sheet for Brabio.
  •  Contact information for patient support service for Brabio.
  •  Template for switching letter for Brabio.

From 1 February 2021, it is HSE policy that all adult patients who are commencing treatment with glatiramer acetate should be prescribed the preferred product Brabio.